| Bioactivity | GSK-3β inhibitor 3 is a potent, selective, irreversible and covalent inhibitor of Glycogen Synthase Kinase 3β (GSK-3β), with an IC50 of 6.6 μM. GSK-3β inhibitor 3 can be used for the research of acute promyelocytic leukemia[1]. | ||||||||||||
| Invitro | GSK-3β inhibitor 3 (compound 4-3) (100 μM) inhibits GSK-3α activity by 87.3%[1].GSK-3β inhibitor 3 (6.25-100 μM; 24-48 h) dose-dependently inhibits the growth of NB4 and NB4-R1 cells[1].GSK-3β inhibitor 3 (12.5-100 μM; 24 h) significantly increases the percentage of apoptosis in a dose-dependent pattern in NB4 and NB4-R1 cells[1]. Cell Viability Assay[1] Cell Line: | ||||||||||||
| Name | GSK-3β inhibitor 3 | ||||||||||||
| CAS | 1448990-73-5 | ||||||||||||
| Formula | C18H14FNO2S | ||||||||||||
| Molar Mass | 327.37 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
GSK-3β inhibitor 3
CAS: 1448990-73-5 F: C18H14FNO2S W: 327.37
GSK-3β inhibitor 3 is a potent, selective, irreversible and covalent inhibitor of Glycogen Synthase Kinase 3β (GSK-3β
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.